MARVELD1 anticorps (N-Term)

N° du produit ABIN500236

Détail du produit anti-MARVELD1 anticorps

Antigène: MARVELD1 (MARVEL Domain Containing 1 (MARVELD1))

Épitope: N-Term

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp MARVELD1 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Réactivité croisée (Details): Species reactivity (tested):Human, mouse, rat

Purification: Peptide affinity chromatography

Immunogène: MARVELD1 antibody was raised against a 16 amino acid peptide from near the amino terminus of human MARVELD1.

Isotype: IgG

Information d'application

Indications d'application: ELISA. Western blot.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: PBS containing 0.02 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: Store the antibody (in aliquots) at -20 °C.

Détails sur MARVELD1

Antigène: MARVELD1 (MARVEL Domain Containing 1 (MARVELD1))

Autre désignation: MARVELD1 (MARVELD1 Produits)

Synonymes: anticorps Mrvldc1, anticorps AI504298, anticorps GB14, anticorps MARVD1, anticorps MRVLDC1, anticorps RP11-548K23.8, anticorps bA548K23.8, anticorps MARVEL domain containing 1, anticorps MARVEL (membrane-associating) domain containing 1, anticorps Marveld1, anticorps MARVELD1

Sujet: MARVELD1, (MARVEL domain-containing 1), is one of the MARVEL (MAL and related proteins for vesicle trafficking and membrane link) domain-containing proteins. It is a nuclear-localized protein that is widely expressed in normal human tissues. While it has been reported to be overexpressed in colon cancer, MARVELD1 protein levels are generally lower in several primary tumors including ovary, breast, kidney, bladder and liver. This lower level of MARVELD1 expression in tumors is thought to be due to a higher methylation status of the MARVELD1 promoter as treatment of MDA-MB-361 with 5-aza-2'-deoxycytidine restores MARVELD1 expression (1,3), suggesting that loss of MARVELD1 expression may contribute to tumorgenicity.Synonyms: MARVEL domain-containing protein 1, MRVLDC1

ID gène: 83742

UniProt: Q9BSK0